<DOC>
	<DOC>NCT02996916</DOC>
	<brief_summary>Hypertension is a leading risk factor for morbidity and mortality worldwide. The brain is a major target of the damaging effects of hypertension. Hypertension has been recognized as the leading cause of dementia as well as the most important risk factor for stroke and vascular cognitive impairment. Although glucose is the principal cerebral energy source, impact of hypertensive treatment on cerebral glucose metabolism is poorly understood.</brief_summary>
	<brief_title>Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Written informed consent obtained Male and female subjects aged 20 years or older at informed consent Essential hypertension who had never received angiotensin II receptor antagonists and calcium channel blockers Secondary hypertension or malignant hypertension Diabetes mellitus History or evidence of a stroke Hepatic or hematologic abnormality Mild Cognitive Impairment or Dementia Serum potassium level ≥ 5.5 mEq/L Serum creatinine level ≥ 3.0 mg/dL Acute or chronic disease Allergy to any drugs Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>